Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

BACKGROUND: To evaluate safety, pharmacokinetics, and maximum tolerated dose of roniciclib in patients with advanced malignancies, with dose expansion to evaluate clinical benefit at the recommended phase II dose (RP2D). METHODS: Two phase I dose-escalation studies evaluated two roniciclib dosing sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahleda, Rastislav, Grilley-Olson, Juneko E, Govindan, Ramaswamy, Barlesi, Fabrice, Greillier, Laurent, Perol, Maurice, Ray-Coquard, Isabelle, Strumberg, Dirk, Schultheis, Beate, Dy, Grace K, Zalcman, Gérard, Weiss, Glen J, Walter, Annette O, Kornacker, Martin, Rajagopalan, Prabhu, Henderson, David, Nogai, Hendrik, Ocker, Matthias, Soria, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518866/
https://www.ncbi.nlm.nih.gov/pubmed/28463960
http://dx.doi.org/10.1038/bjc.2017.92

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518866/
https://www.ncbi.nlm.nih.gov/pubmed/28463960
http://dx.doi.org/10.1038/bjc.2017.92

Ejemplares similares